Catalyst Pharmaceutical
CPRX
316 hedge funds and large institutions have $1.9B invested in Catalyst Pharmaceutical in 2024 Q3 according to their latest regulatory filings, with 67 funds opening new positions, 98 increasing their positions, 105 reducing their positions, and 21 closing their positions.
219% more first-time investments, than exits
New positions opened: 67 | Existing positions closed: 21
27% more capital invested
Capital invested by funds: $1.5B → $1.9B (+$398M)
17% more funds holding
Funds holding: 271 → 316 (+45)
7% less repeat investments, than reductions
Existing positions increased: 98 | Existing positions reduced: 105
1.58% less ownership
Funds ownership: 82.06% → 80.48% (-1.6%)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
61% less call options, than puts
Call options by funds: $610K | Put options by funds: $1.58M
Top Buyers
| 1 |
Morgan Stanley
New York
|
+$15M |
| 2 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$9.98M |
| 3 |
Millennium Management
New York
|
+$7.97M |
| 4 |
Skandinaviska Enskilda Banken (SEB)
Stockholm,
Sweden
|
+$7.78M |
| 5 |
Goldman Sachs
New York
|
+$7.12M |
Top Sellers
| 1 |
DM
Deerfield Management
New York
|
-$53.7M |
| 2 |
Janus Henderson Group
London,
United Kingdom
|
-$33.7M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$10.3M |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$9.78M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$9.58M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
GS
326
GTS Securities
New York
| – | -$183K | -11,845 | Closed |
|
|
PAM
327
PVG Asset Management
Golden,
Colorado
| – | -$183K | -11,786 | Closed |
|
|
EFM
328
E Fund Management
Guangzhou,
China
| – | -$175K | -11,266 | Closed |
|
329
Wolverine Trading
Chicago,
Illinois
| – | -$164K | -10,609 | Closed |
|
330
Daiwa Securities Group
Tokyo,
Japan
| – | -$158K | -10,200 | Closed |
|
|
PAS
331
Point72 Asia (Singapore)
Singapore
| – | -$153K | -9,857 | Closed |
|
|
CSS
332
Cubist Systematic Strategies
Stamford,
Connecticut
| – | -$132K | -8,523 | Closed |
|
|
NVCHI
333
New Vernon Capital Holdings II
Morristown,
New Jersey
| – | -$122K | -7,864 | Closed |
|
|
IC
334
Innealta Capital
Austin,
Texas
| – | -$2.51K | -162 | Closed |
|
|
NA
335
NewEdge Advisors
New Orleans,
Louisiana
| – | -$1.08K | -70 | Closed |
|
|
APC
336
Aspire Private Capital
Cornelius,
North Carolina
| – | -$310 | -20 | Closed |
|
|
HWM
337
Hemington Wealth Management
Falls Church,
Virginia
| – | +$37 | +2 | New |
|
CPRX Hedge Fund Activity: Q3 2024 in Review
316 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q3 2024, worth a combined $1.9B — up 27% from $1.5B a quarter earlier.
Buyers outnumbered sellers: 67 funds opened new CPRX positions and 21 closed out — a net gain of 46 holders — while 98 added to existing stakes and 105 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $15M. The largest seller was Deerfield Management, cutting an estimated $53.7M.
- 316 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q3 2024, up from 271 in Q2 2024.
- Funds reported $1.9B of Catalyst Pharmaceutical stock for Q3 2024, up 27% quarter-over-quarter.
- 67 funds opened new Catalyst Pharmaceutical positions in Q3 2024 and 21 closed out, a net change of +46 holders.
- The largest Catalyst Pharmaceutical buyer in Q3 2024 was Morgan Stanley, an estimated $15M added.
- The largest Catalyst Pharmaceutical seller in Q3 2024 was Deerfield Management, an estimated $53.7M sold.
Based on aggregated 13F filings for Q3 2024.